Antibody-Armed Platelets for the Regenerative Targeting of Endogenous Stem Cells.

Loading...
Thumbnail Image

Date

2019-03

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

17
views
10
downloads

Citation Stats

Abstract

Stem cell therapies have shown promise in treating acute and chronic ischemic heart disease. However, current therapies are limited by the low retention and poor integration of injected cells in the injured tissue. Taking advantage of the natural infarct-homing ability of platelets, we engineered CD34 antibody-linked platelets (P-CD34) to capture circulating CD34-positive endogenous stem cells and direct them to the injured heart. In vitro, P-CD34 could bind to damaged aortas and capture endogenous stem cells in whole blood. In a mouse model of acute myocardial infarction, P-CD34 accumulated in the injured heart after intravenous administration, leading to a concentration of endogenous CD34 stem cells in the injured heart for effective heart repair. This represents a new technology for endogenous stem cell therapy.

Department

Description

Provenance

Citation

Published Version (Please cite this version)

10.1021/acs.nanolett.8b04970

Publication Info

Shen, Deliang, Zhenhua Li, Shiqi Hu, Ke Huang, Teng Su, Hongxia Liang, Feiran Liu, Ke Cheng, et al. (2019). Antibody-Armed Platelets for the Regenerative Targeting of Endogenous Stem Cells. Nano letters, 19(3). pp. 1883–1891. 10.1021/acs.nanolett.8b04970 Retrieved from https://hdl.handle.net/10161/26322.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Su

Teng Su

Assistant Professor in Medicine

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.